Repurposing of the antimalarial agent tafenoquine to combat MRSA

mSystems. 2023 Dec 21;8(6):e0102623. doi: 10.1128/msystems.01026-23. Epub 2023 Dec 4.

Abstract

This study represents the first investigation into the antimicrobial effect of TAF against S. aureus and its potential mechanisms. Our data highlighted the effects of TAF against MRSA planktonic cells, biofilms, and persister cells, which is conducive to broadening the application of TAF. Through mechanistic studies, we revealed that TAF targets bacterial cell membranes. In addition, the in vivo experiments in mice demonstrated the safety and antimicrobial efficacy of TAF, suggesting that TAF could be a potential antibacterial drug candidate for the treatment of infections caused by multiple drug-resistant S. aureus.

Keywords: antimicrobial agents; drug repurposing; methicillin-resistant Staphylococcus aureus; tafenoquine.

MeSH terms

  • Animals
  • Anti-Infective Agents* / pharmacology
  • Antimalarials* / pharmacology
  • Drug Repositioning
  • Methicillin-Resistant Staphylococcus aureus*
  • Mice
  • Staphylococcus aureus

Substances

  • Antimalarials
  • tafenoquine
  • Anti-Infective Agents